PUBLISHER: The Business Research Company | PRODUCT CODE: 1942503
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942503
The buccal drug delivery system involves administering the desired medicine through the buccal mucosal membrane lining of the mouth cavity. This method is effective for delivering mucosal and transmucosal drugs. Mucosal drug delivery aims for site-specific drug release on the mucosa, whereas transmucosal permeation entails drug absorption across the mucosal barrier and into the systemic circulation.
The main types of buccal drug delivery systems include sublingual, buccal tablets and lozenges, and oral sprays. The term sublingual refers to the route of administration for systemic medication delivery of buccal drugs. These are applied in various applications such as pain management, smoking cessation, and angina pectoris, and are utilized by hospitals, ambulatory care centers, and other healthcare facilities.
Tariffs are impacting the buccal drug delivery system market by increasing costs of imported pharmaceutical excipients, packaging materials, specialized manufacturing equipment, and quality testing instruments. Pharmaceutical manufacturers in North America and Europe are most affected due to reliance on imported formulation inputs, while Asia-Pacific faces cost pressure on finished product exports. These tariffs are increasing production costs and extending development timelines. However, they are also supporting local excipient production, regional manufacturing expansion, and innovation in cost-efficient formulation technologies.
The buccal drug delivery system market research report is one of a series of new reports from The Business Research Company that provides buccal drug delivery system market statistics, including buccal drug delivery system industry global market size, regional shares, competitors with a buccal drug delivery system market share, detailed buccal drug delivery system market segments, market trends and opportunities, and any further data you may need to thrive in the buccal drug delivery system industry. This buccal drug delivery system market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The buccal drug delivery system market size has grown rapidly in recent years. It will grow from $3.89 billion in 2025 to $4.32 billion in 2026 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to increasing preference for alternative drug delivery routes, growth in chronic pain and angina treatments, advancements in mucoadhesive formulations, rising demand for faster onset medications, expansion of oral pharmaceutical manufacturing.
The buccal drug delivery system market size is expected to see rapid growth in the next few years. It will grow to $6.48 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to increasing investments in transmucosal drug research, rising demand for smoking cessation therapies, expansion of personalized drug delivery systems, growing focus on compliance-friendly formulations, increasing development of novel buccal drugs. Major trends in the forecast period include increasing adoption of buccal and sublingual dosage forms, rising demand for rapid drug absorption systems, growing focus on patient-friendly drug delivery, expansion of controlled-release buccal formulations, enhanced emphasis on non-invasive therapies.
The increasing prevalence of chronic diseases is anticipated to boost the growth of the buccal drug delivery systems market in the future. Chronic diseases are defined as health conditions that last for a year or more, including cancer, heart disease, stroke, diabetes, and arthritis. These illnesses are among the most common chronic conditions that can be managed but not cured, requiring ongoing medical care and nutrition. Buccal drug delivery systems offer an effective and suitable method for administering mucosal and transmucosal drugs needed by many patients suffering from chronic diseases such as diabetes and cancer. For instance, in September 2023, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported that 41 million deaths, accounting for 74% of global deaths caused by non-communicable diseases (NCDs) or chronic diseases, occur each year. Among these, there were 17.9 million deaths due to cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Thus, the increasing prevalence of chronic diseases is driving the growth of the buccal drug delivery systems market.
Leading players in the buccal drug delivery systems space are emphasizing new product introductions, such as melatonin oral sprays, to support revenue growth. A melatonin oral spray is a melatonin supplement delivered in a spray form for oral administration, enabling convenient and efficient use. For example, in February 2023, Arlak Biotech Private Limited, an India-based pharmaceutical company, introduced a melatonin oral spray. The product supports the body's natural melatonin production, helping to enhance sleep quality through a simple and effective delivery method. It provides rapid relief for individuals experiencing difficulty falling asleep, staying asleep, or adapting to changing sleep schedules. Owing to its fast and easy oral absorption, the spray enables a quicker onset of sleep and contributes to improved overall sleep quality.
In April 2023, DifGen Pharmaceuticals LLC, a United States-based pharmaceutical company, acquired Aveva Drug Delivery Services Inc. for an undisclosed consideration. The transaction was intended to enhance patient access to essential, life-saving medicines that are consistently high in quality and offered at affordable costs. This acquisition enabled DifGen to strengthen its research and development and manufacturing capabilities, while supporting a secure supply chain and the production of complex dosage forms for its partners through localized manufacturing operations in the United States. Aveva Drug Delivery Services Inc. is a United States-based company specializing in buccal drug delivery system solutions.
Major companies operating in the buccal drug delivery system market are Teva Pharmaceuticals Industries Ltd, Pfizer Incorporated, GlaxoSmithKline Public Limited Company, Indivior PLC, Generex Biotechnology Corporation, Catalent Inc, Arx Limited Liability Company, BioDelivery Science International Incorporated, Cynapsus Therapeutics Incorporated, Endo Pharmaceuticals Public Limited Company, Medlab Clinical Ltd, AstraZeneca PLC, Dr. Reddy's Laboratories Ltd, Takeda Pharmaceutical Company Limited, Novartis AG, Sanofi SA, Bayer AG, Adare Pharmaceuticals Inc, NAPP Pharmaceutical Ltd, Perrigo Company PLC, Reckitt Benckiser Group PLC, Teligent Pharma Inc, Par Pharmaceutical Companies Inc, Acorda Therapeutics Inc, Opiant Pharmaceuticals Inc
North America was the largest region in the buccal drug delivery systems market share in 2025. The regions covered in the buccal drug delivery system market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the buccal drug delivery system market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The buccal drug delivery system market consists of the sales of drug ingredients such as insulin, nicotine, tizanidine, triptan, nifedipine, flurbiprofen, sodium carboxymethylcellulose, carbopol, glibenclamide, hyaluronic acid, and xanthan gum. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Buccal Drug Delivery System Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses buccal drug delivery system market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for buccal drug delivery system ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The buccal drug delivery system market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.